Antimicrobial Drug Discovery
A Metabolism-Informed Neural Network Identifies Pathways Influencing the Potency and Toxicity of Antimicrobial Combinations
This groundbreaking research introduces CALMA, a novel computational framework that integrates genome-scale metabolic modeling with a neural network to predict the potency and toxicity of multi-drug combinations. CALMA offers a rational, mechanistic approach to streamline combination treatment design, significantly reducing the experimental search space by 97% and identifying promising antimicrobial combinations with reduced toxicity.
Quantifiable Impact
CALMA's innovative approach delivers measurable improvements in drug discovery, from optimizing search efficiency to enhancing predictive accuracy for safer treatments.
0
Reduction in Experimental Search Space
0
Reduction in Model Parameters
0
Highest Correlation (M. tuberculosis Toxicity)
Deep Analysis & Enterprise Applications
Select a topic to dive deeper, then explore the specific findings from the research, rebuilt as interactive, enterprise-focused modules.
CALMA, a novel computational framework, revolutionizes drug combination design by integrating genome-scale metabolic modeling with an artificial neural network. It significantly reduces experimental burden and enhances interpretability, paving the way for safer and more effective antimicrobial treatments.
CALMA's methodology involves three key steps: simulating metabolic reaction fluxes using GEMs, constructing joint profile features from this data, and employing an ANN to predict drug combination potency and toxicity. Its unique architecture, inspired by metabolic subsystems, drastically reduces model parameters and improves generalizability.
CALMA achieved significant accuracy in predicting drug combination potency and toxicity across various datasets. It identified crucial metabolic pathways, such as nucleotide salvage, influencing toxicity, a finding validated through in vitro experiments and real-world health record analysis showing reduced nephrotoxicity for specific combinations.
91.46%
Toxicity Increase from Nucleotide Salvage Pathway Knock-off
Enterprise Process Flow
Simulate Metabolic Reaction Fluxes (GEMs)
→
Process Flux Data (Joint Profile Features)
→
Develop ANN Model
→
Predict Potency & Toxicity Scores
| Metric | INDIGO | MAGENTA | CARAMEL | RF + GEMs | CALMA |
|---|---|---|---|---|---|
| Integration with Metabolic Models | X | X | ✓ | ✓ | ✓ |
| Metabolic Architecture of the Model | X | X | X | X | ✓ |
| Model Interpretation | X | X | X | ✓ | ✓✓✓ |
| Potency (or Synergy) Prediction | ✓ | ✓ | ✓ | ✓ | ✓ |
| Toxicity Prediction | X | X | X | ✓ | ✓ |
Real-World Validation: Vancomycin Combinations
Mining health records of over 330 million deidentified US patients revealed a 23% reduced risk of nephrotoxicity (kidney side-effects) in patients co-administered Vancomycin with Azithromycin, a combination identified by CALMA. This real-world evidence corroborates CALMA's predictions and highlights the potential for designing safer drug regimens, particularly regarding organ-specific toxicities.
Project Your Enterprise ROI
Our AI-powered framework optimizes drug combination design, significantly reducing the time and resources typically consumed by empirical screening. By leveraging mechanistic insights, CALMA minimizes the risk of suboptimal efficacy and inadvertent toxicity, leading to faster drug development cycles and safer treatments.
Estimated Annual Savings
Annual Hours Reclaimed
Implementation Roadmap
Our structured approach ensures a seamless integration of CALMA into your existing drug discovery pipeline, maximizing its benefits from day one.
Phase 1: Data Integration & Model Training
Integrate existing omics data, GEMs, and toxicity databases. Train CALMA's neural network on diverse drug combinations for potency and toxicity prediction.
Phase 2: Pathway Identification & Prioritization
Utilize CALMA's interpretability features to identify key metabolic pathways influencing drug interactions. Prioritize targets for experimental validation.
Phase 3: In Vitro Validation & Optimization
Experimentally validate promising drug combinations and pathway modulation strategies in relevant cell lines. Refine predictions based on empirical results.
Phase 4: Clinical Translation & Impact Assessment
Support the design of novel, safer, and more effective antimicrobial regimens for clinical trials. Monitor real-world outcomes and continuously improve the model.
Ready to Transform Your Drug Discovery?
Unlock the full potential of AI-driven drug combination design with CALMA. Schedule a consultation to discuss how our solution can accelerate your research and deliver safer, more effective treatments.
Ready to Get Started?
Book Your Free Consultation.
Let's Discuss Your AI Strategy!
Lets Discuss Your Needs
Select a Date
Sun
Mon
Tue
Wed
Thu
Fri
Sat